Therapeutic Area

Respiratory

Therapeutic area intelligence for Respiratory with 11 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 11
Catalysts: 0
Companies: 4

Companies

Assets

Recent signals(11)

ClinicalJune 21, 2026

Amgen's AMG 691 Phase 1 Study Targets Safety in Asthma Patients

Amgen is conducting Phase 1 study to evaluate the safety and tolerability of AMG 691 in healthy participants and those with mild-to-moderate asthma.

StrategyJune 21, 2026

Budget Impact of Single-Inhaler Triple Therapy for Asthma in Saudi Arabia

The study evaluates the financial implications of introducing FF/UMEC/VI therapy for asthma in Saudi Arabia.

RegulatoryJune 21, 2026

FDA Accepts Supplement for Provocholine (Methacholine Chloride) by Methapharm

The FDA has accepted a supplemental application for Provocholine, indicating ongoing regulatory progress.

StrategyJune 20, 2026

FDA Approves Albuterol Sulfate ANDA219409 from Cipla

The FDA has approved ANDA219409 for Albuterol Sulfate submitted by Cipla.

ClinicalJune 18, 2026

Study Reveals Mucus-Plug Dynamics in COPD Patients and Ex-Smokers

In a study of ex-smokers, mucus-plugs persisted in one-third of patients with COPD, while new plugs developed in others, indicating complex dynamics.

ClinicalJune 18, 2026

EVOLVE Study to Assess Real-World Effectiveness of Tezepelumab in Severe Asthma in Greece

The EVOLVE study will evaluate the real-world effectiveness of tezepelumab in uncontrolled severe asthma over two years in Greece.

CompetitiveJune 17, 2026

Phase 3 Study of BLU-5937 Shows Promise for Refractory Chronic Cough

A Phase 3 study is underway to evaluate the efficacy and safety of BLU-5937 in adults with refractory chronic cough.

ClinicalJune 16, 2026

Tozorakimab Shows Positive Phase III Results in COPD, Reducing Exacerbations

Tozorakimab met its primary endpoint in the Phase III MIRANDA trial, showing significant reduction in COPD exacerbations.

ClinicalJune 2, 2026

Tozorakimab achieves primary endpoints in Phase III trials for COPD

Tozorakimab met primary endpoints in both OBERON and TITANIA Phase III trials, showing significant reductions in COPD exacerbations.

ClinicalJune 1, 2026

Study on NMES for Functional Recovery in COPD and Pneumonia Patients

A clinical trial is investigating the feasibility of neuromuscular electrical stimulation (NMES) to improve recovery in older adults with AECOPD and community-acquired pneumonia.

RegulatoryJune 1, 2026

Breztri Gains US Approval as First Triple Therapy for Asthma

Breztri has been approved in the US as the first and only triple therapy for asthma in patients aged 12 and older, based on positive Phase III trial results.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Asthma →

COPD →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.